Takeda Pharmaceutical Company (TAK) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChartTranscripts

Takeda Pharmaceutical Company Revenue Highlights


Latest Revenue (Y)

$4.26T

Latest Revenue (Q)

$1.05T

Main Segment (Y)

Gastroenterology

Main Geography (Y)

UNITED STATES

Takeda Pharmaceutical Company Revenue by Period


Takeda Pharmaceutical Company Revenue by Year

DateRevenueChange
2024-03-31$4.26T5.87%
2023-03-31$4.03T12.85%
2022-03-31$3.57T11.61%
2021-03-31$3.20T-2.84%
2020-03-31$3.29T56.93%
2019-03-31$2.10T18.45%
2018-03-31$1.77T2.22%
2017-03-31$1.73T-4.17%
2016-03-31$1.81T1.66%
2015-03-31$1.78T5.09%
2014-03-31$1.69T8.63%
2013-03-31$1.56T3.20%
2012-03-31$1.51T6.31%
2011-03-31$1.42T-3.18%
2010-03-31$1.47T-4.70%
2009-03-31$1.54T11.90%
2008-03-31$1.37T5.34%
2007-03-31$1.31T7.67%
2006-03-31$1.21T7.95%
2005-03-31$1.12T3.36%
2004-03-31$1.09T3.86%
2003-03-31$1.05T4.08%
2002-03-31$1.01T4.32%
2001-03-31$963.48B4.37%
2000-03-31$923.13B-

Takeda Pharmaceutical Company generated $4.26T in revenue during NA 2024, up 5.87% compared to the previous quarter, and up 203.31% compared to the same period a year ago.

Takeda Pharmaceutical Company Revenue by Quarter

DateRevenueChange
2024-03-31$1.05T-5.43%
2023-12-31$1.11T6.53%
2023-09-30$1.04T-1.47%
2023-06-30$1.06T10.72%
2023-03-31$956.16B-12.80%
2022-12-31$1.10T9.40%
2022-09-30$1.00T3.07%
2022-06-30$972.47B11.36%
2022-03-31$873.29B-3.11%
2021-12-31$901.29B6.68%
2021-09-30$844.82B-11.03%
2021-06-30$949.60B23.28%
2021-03-31$770.27B-7.94%
2020-12-31$836.75B6.06%
2020-09-30$788.93B-1.61%
2020-06-30$801.85B3.91%
2020-03-31$771.70B-10.20%
2019-12-31$859.32B5.95%
2019-09-30$811.05B-4.48%
2019-06-30$849.12B18.39%
2019-03-31$717.21B43.61%
2018-12-31$499.40B15.93%
2018-09-30$430.78B-4.24%
2018-06-30$449.83B12.19%
2018-03-31$400.96B-17.86%
2017-12-31$488.15B12.69%
2017-09-30$433.18B-3.36%
2017-06-30$448.24B7.70%
2017-03-31$416.20B-10.50%
2016-12-31$465.05B11.58%
2016-09-30$416.80B-3.97%
2016-06-30$434.00B4.80%
2016-03-31$414.12B-15.35%
2015-12-31$489.21B6.87%
2015-09-30$457.75B2.57%
2015-06-30$446.30B1.93%
2015-03-31$437.84B-10.40%
2014-12-31$488.63B11.00%
2014-09-30$440.20B7.07%
2014-06-30$411.15B1.57%
2014-03-31$404.81B-11.77%
2013-12-31$458.82B9.83%
2013-09-30$417.74B1.81%
2013-06-30$410.30B11.45%
2013-03-31$368.16B-8.46%
2012-12-31$402.17B3.48%
2012-09-30$388.64B-2.42%
2012-06-30$398.29B4.45%
2012-03-31$381.32B-10.30%
2011-12-31$425.11B23.12%
2011-09-30$345.28B-3.34%
2011-06-30$357.22B5.61%
2011-03-31$338.25B-7.86%
2010-12-31$367.11B2.16%
2010-09-30$359.33B1.31%
2010-06-30$354.70B4.93%
2010-03-31$338.02B-9.25%
2009-12-31$372.49B-1.06%
2009-09-30$376.48B-0.66%
2009-06-30$378.98B12.93%
2009-03-31$335.58B-15.18%
2008-12-31$395.62B-3.57%
2008-09-30$410.26B-

Takeda Pharmaceutical Company generated $1.05T in revenue during Q4 2024, up -5.43% compared to the previous quarter, and up 95.83% compared to the same period a year ago.

Takeda Pharmaceutical Company Revenue Breakdown


Takeda Pharmaceutical Company Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceMar 24Mar 23Mar 22Mar 21Mar 20
Adcetris$109.42B$83.94B$69.19B$59.43B$52.67B
Adderall XR$41.76B$24.30B---
Advate$122.91B$118.19B$118.49B$128.53B$157.86B
Adynovate/Adynovi$66.31B$66.55B$60.73B--
Albumin$133.99B$121.45B$90.03B$57.58B$67.22B
Alofisel$3.51B$2.73B$1.84B$784.00M$373.00M
Alunbrig$28.52B$20.56B$13.64B$8.81B$7.24B
Azilva-F$33.64B$72.90B$76.30B$82.20B$76.75B
Dexilant$45.28B$69.37B$50.76B$55.57B$62.80B
Elaprase$91.56B$85.32B$73.12B$68.79B$67.92B
Entyvio$800.92B$702.74B$521.78B$429.28B$347.20B
Feiba$40.54B$41.27B$39.16B--
Fosrenol$13.53B----
Gastroenterology$1.22T$1.09T$875.68B$777.80B$697.90B
Gattex/Revestive$119.25B$93.08B$75.75B$64.56B$61.81B
Iclusig$54.71B$47.21B$34.86B$34.19B$31.82B
Immunoglobulin$644.59B$522.21B$385.86B$334.87B$298.70B
Intuniv$33.55B----
Leuplin/Enantone$107.35B$111.31B$106.46B--
Neuroscience$627.01B$637.71B$482.29B$417.30B$438.52B
Ninlaro$87.36B$92.69B$91.20B$87.40B$77.56B
Oncology$462.36B$438.74B$468.73B$416.51B$420.96B
Other Gastroenterology$82.23B$72.39B$82.88B$99.66B$103.54B
Other PDT Immunology$39.99B$34.79B$31.05B$27.93B$28.25B
Other Product$368.91B$454.60B$624.15B$574.07B$704.76B
Other Product, Other$321.74B$364.97B$515.16B$402.43B$538.30B
Other Rare Hematology$47.30B$46.37B$53.01B$45.31B$66.20B
PDT Immunology$818.57B$678.44B$506.95B$420.39B$394.17B
Pantoloc/Controloc$46.49B$45.52B$40.27B--
Rare Diseases$770.70B$723.44B$591.75B$634.89B-
Rare Hematology$305.30B$304.72B$283.69B$289.80B$334.24B
Recombinate$12.05B$12.76B$12.30B--
Replagal$73.55B$66.74B$51.71B$51.76B$51.25B
Takhzyro$178.68B$151.80B$103.24B$86.72B$68.27B
Trintellix$104.80B$100.08B$82.31B$68.87B$70.67B
Velcade$5.54B$27.76B$110.05B$101.11B$118.32B
Vpriv$51.30B$48.37B$42.41B$38.52B$38.01B
Vyvanse/Elvanse$423.22B$459.29B$327.05B--
Lotriga-$16.73B$32.69B$31.77B$31.75B
Other Oncology--$43.33B$30.21B$24.31B
Other Hereditary Angioedema--$23.65B$25.79B-
Natpara/Natpar--$5.35B--
Other Neuroscience--$72.93B$76.90B$69.47B
Rare Metabolic--$172.59B$162.62B$170.82B
Takecab-F--$102.40B$84.82B$72.71B
Diabetes--$133.04B--
Firazyr--$26.69B$26.82B$32.66B
Hereditary Angioedema--$153.59B$139.33B$129.82B
Vyvanse---$271.53B$274.08B
RECOMBINATE---$13.39B-
PANTOPRAZOLE---$43.12B$49.46B
Nesina-F---$57.67B$57.96B
Natpara---$3.55B$13.63B
Leuprorelin---$95.36B$109.05B
FEIBA---$44.49B$51.51B
Adynovate---$58.07B$58.67B
Cinryze----$24.35B
Kalbitor----$4.54B

Takeda Pharmaceutical Company's latest annual revenue breakdown by segment (product or service), as of Mar 24: Gastroenterology (14.25%), PDT Immunology (9.59%), Entyvio (9.38%), Rare Diseases (9.03%), Immunoglobulin (7.55%), Neuroscience (7.35%), Oncology (5.42%), Vyvanse/Elvanse (4.96%), Other Product (4.32%), Other Product, Other (3.77%), Rare Hematology (3.58%), Takhzyro (2.09%), Albumin (1.57%), Advate (1.44%), Gattex/Revestive (1.40%), Adcetris (1.28%), Leuplin/Enantone (1.26%), Trintellix (1.23%), Elaprase (1.07%), Ninlaro (1.02%), Other Gastroenterology (0.96%), Replagal (0.86%), Adynovate/Adynovi (0.78%), Iclusig (0.64%), Vpriv (0.60%), Other Rare Hematology (0.55%), Pantoloc/Controloc (0.54%), Dexilant (0.53%), Adderall XR (0.49%), Feiba (0.48%), Other PDT Immunology (0.47%), Azilva-F (0.39%), Intuniv (0.39%), Alunbrig (0.33%), Fosrenol (0.16%), Recombinate (0.14%), Velcade (0.06%), and Alofisel (0.04%).

Takeda Pharmaceutical Company Revenue Breakdown by Country

Annual Revenue by Country

CountryMar 24Mar 23Mar 22Mar 21Mar 20
Asia, Excluding Japan$261.22B$225.01B$196.96B--
UNITED STATES$2.20T$2.10T$1.71T$1.57T$1.60T
Other Countries Not Separately Reported$117.91B$95.18B$68.94B$68.52B$71.26B
Latin America$198.10B$160.38B$128.47B$121.64B$143.46B
JAPAN$451.39B$512.04B$658.98B$559.75B$592.79B
Europe And Canada$966.84B$842.67B$739.17B$666.18B$645.53B
Azilva-F--$76.30B--
Alunbrig--$13.64B--
Alofisel--$1.84B--
Albumin--$90.03B--
Adynovate/Adynovi--$60.73B--
Advate--$118.49B--
Adcetris--$69.19B--
Lotriga--$32.69B--
Immunoglobulin--$385.86B--
Iclusig--$34.86B--
Hereditary Angioedema--$153.59B--
Gattex/Revestive--$75.75B--
Gastroenterology--$875.68B--
Firazyr--$26.69B--
Feiba--$39.16B--
Entyvio--$521.78B--
Elaprase--$73.12B--
Diabetes--$133.04B--
Dexilant--$50.76B--
Velcade--$110.05B--
Trintellix--$82.31B--
Takhzyro--$103.24B--
Takecab-F--$102.40B--
Other Oncology--$43.33B--
Other Neuroscience--$72.93B--
Other Hereditary Angioedema--$23.65B--
Other Gastroenterology--$82.88B--
Oncology--$468.73B--
Ninlaro--$91.20B--
Neuroscience--$482.29B--
Natpara/Natpar--$5.35B--
Leuplin/Enantone--$106.46B--
Vyvanse/Elvanse--$327.05B--
Vpriv--$42.41B--
Replagal--$51.71B--
Recombinate--$12.30B--
Rare Metabolic--$172.59B--
Rare Hematology--$283.69B--
Pantoloc/Controloc--$40.27B--
PDT Immunology--$506.95B--
Other Rare Hematology--$53.01B--
Other Product, Other--$515.16B--
Other Product--$624.15B--
Other PDT Immunology--$31.05B--
Asia---$156.24B$165.40B

Takeda Pharmaceutical Company's latest annual revenue breakdown by geography, as of Mar 24: UNITED STATES (52.39%), Europe And Canada (23.07%), JAPAN (10.77%), Asia, Excluding Japan (6.23%), Latin America (4.73%), and Other Countries Not Separately Reported (2.81%).

Takeda Pharmaceutical Company Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
TAKTakeda Pharmaceutical Company$4.26T$1.05T
TEVATeva Pharmaceutical Industries$15.85B$4.16B
VTRSViatris$15.43B$3.66B
HLNHaleon$11.30B$2.92B
BHCBausch Health Companies$8.76B$2.51B
ZTSZoetis$8.54B$2.36B
ELANElanco Animal Health$4.42B$1.21B
CTLTCatalent$4.38B$1.07B
NBIXNeurocrine Biosciences$1.89B$622.10M
PBHPrestige Consumer Healthcare$1.13B$267.14M
EBSEmergent BioSolutions$1.05B$254.70M
PAHCPhibro Animal Health$977.89M$263.22M
EVOEvotec SE$781.43M$208.73M
PCRXPacira BioSciences$674.98M$178.02M
AMPHAmphastar Pharmaceuticals$593.24M$182.39M
COLLCollegium Pharmaceutical$566.77M$144.92M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
SIGASIGA$139.92M$21.81M
ESPREsperion Therapeutics$116.33M$73.83M

TAK Revenue FAQ


Takeda Pharmaceutical Company's yearly revenue for 2024 was $4.26T, representing an increase of 5.87% compared to 2023. The company's yearly revenue for 2023 was $4.03T, representing an increase of 12.85% compared to 2022. TAK's yearly revenue for 2022 was $3.57T, representing an increase of 11.61% compared to 2021.

Takeda Pharmaceutical Company's quarterly revenue for Q4 2024 was $1.05T, a -5.43% decrease from the previous quarter (Q3 2024), and a 9.91% increase year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $1.11T, a 6.53% increase from the previous quarter (Q2 2024), and a 1.33% increase year-over-year (Q3 2023). TAK's quarterly revenue for Q2 2024 was $1.04T, a -1.47% decrease from the previous quarter (Q1 2024), and a 4.07% increase year-over-year (Q2 2023).

Takeda Pharmaceutical Company's revenue growth rate for the last 3 years (2022-2024) was 19.47%, and for the last 5 years (2020-2024) was 29.55%.

Takeda Pharmaceutical Company's revenue streams in r 24 are Adcetris, Adderall XR, Advate, Adynovate/Adynovi, Albumin, Alofisel, Alunbrig, Azilva-F, Dexilant, Elaprase, Entyvio, Feiba, Fosrenol, Gastroenterology, Gattex/Revestive, Iclusig, Immunoglobulin, Intuniv, Leuplin/Enantone, Neuroscience, Ninlaro, Oncology, Other Gastroenterology, Other PDT Immunology, Other Product, Other Product, Other, Other Rare Hematology, PDT Immunology, Pantoloc/Controloc, Rare Diseases, Rare Hematology, Recombinate, Replagal, Takhzyro, Trintellix, Velcade, Vpriv, and Vyvanse/Elvanse. Adcetris generated $109.42B in revenue, accounting 1.28% of the company's total revenue, up 30.37% year-over-year. Adderall XR generated $41.76B in revenue, accounting 0.49% of the company's total revenue, up 71.80% year-over-year. Advate generated $122.91B in revenue, accounting 1.44% of the company's total revenue, up 4.00% year-over-year. Adynovate/Adynovi generated $66.31B in revenue, accounting 0.78% of the company's total revenue, down -0.37% year-over-year. Albumin generated $133.99B in revenue, accounting 1.57% of the company's total revenue, up 10.33% year-over-year. Alofisel generated $3.51B in revenue, accounting 0.04% of the company's total revenue, up 28.92% year-over-year. Alunbrig generated $28.52B in revenue, accounting 0.33% of the company's total revenue, up 38.76% year-over-year. Azilva-F generated $33.64B in revenue, accounting 0.39% of the company's total revenue, down -53.86% year-over-year. Dexilant generated $45.28B in revenue, accounting 0.53% of the company's total revenue, down -34.73% year-over-year. Elaprase generated $91.56B in revenue, accounting 1.07% of the company's total revenue, up 7.31% year-over-year. Entyvio generated $800.92B in revenue, accounting 9.38% of the company's total revenue, up 13.97% year-over-year. Feiba generated $40.54B in revenue, accounting 0.48% of the company's total revenue, down -1.76% year-over-year. Fosrenol generated $13.53B in revenue, accounting 0.16% of the company's total revenue Gastroenterology generated $1.22T in revenue, accounting 14.25% of the company's total revenue, up 11.12% year-over-year. Gattex/Revestive generated $119.25B in revenue, accounting 1.40% of the company's total revenue, up 28.12% year-over-year. Iclusig generated $54.71B in revenue, accounting 0.64% of the company's total revenue, up 15.89% year-over-year. Immunoglobulin generated $644.59B in revenue, accounting 7.55% of the company's total revenue, up 23.43% year-over-year. Intuniv generated $33.56B in revenue, accounting 0.39% of the company's total revenue Leuplin/Enantone generated $107.35B in revenue, accounting 1.26% of the company's total revenue, down -3.56% year-over-year. Neuroscience generated $627.01B in revenue, accounting 7.35% of the company's total revenue, down -1.68% year-over-year. Ninlaro generated $87.36B in revenue, accounting 1.02% of the company's total revenue, down -5.75% year-over-year. Oncology generated $462.36B in revenue, accounting 5.42% of the company's total revenue, up 5.38% year-over-year. Other Gastroenterology generated $82.23B in revenue, accounting 0.96% of the company's total revenue, up 13.59% year-over-year. Other PDT Immunology generated $39.99B in revenue, accounting 0.47% of the company's total revenue, up 14.97% year-over-year. Other Product generated $368.91B in revenue, accounting 4.32% of the company's total revenue, down -18.85% year-over-year. Other Product, Other generated $321.74B in revenue, accounting 3.77% of the company's total revenue, down -11.84% year-over-year. Other Rare Hematology generated $47.3B in revenue, accounting 0.55% of the company's total revenue, up 2.01% year-over-year. PDT Immunology generated $818.57B in revenue, accounting 9.59% of the company's total revenue, up 20.65% year-over-year. Pantoloc/Controloc generated $46.5B in revenue, accounting 0.54% of the company's total revenue, up 2.15% year-over-year. Rare Diseases generated $770.7B in revenue, accounting 9.03% of the company's total revenue, up 6.53% year-over-year. Rare Hematology generated $305.3B in revenue, accounting 3.58% of the company's total revenue, up 0.19% year-over-year. Recombinate generated $12.05B in revenue, accounting 0.14% of the company's total revenue, down -5.58% year-over-year. Replagal generated $73.55B in revenue, accounting 0.86% of the company's total revenue, up 10.21% year-over-year. Takhzyro generated $178.68B in revenue, accounting 2.09% of the company's total revenue, up 17.71% year-over-year. Trintellix generated $104.8B in revenue, accounting 1.23% of the company's total revenue, up 4.71% year-over-year. Velcade generated $5.54B in revenue, accounting 0.06% of the company's total revenue, down -80.05% year-over-year. Vpriv generated $51.3B in revenue, accounting 0.60% of the company's total revenue, up 6.04% year-over-year. Vyvanse/Elvanse generated $423.22B in revenue, accounting 4.96% of the company's total revenue, down -7.85% year-over-year.

For the fiscal year ending Mar 24, the largest source of revenue of Takeda Pharmaceutical Company was Gastroenterology. This segment made a revenue of $1.22T, representing 14.25% of the company's total revenue.